Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway

Liang,Liang; Li,Lei; Zeng,Jin; Gao,Yang; Chen,Yu-Le; Wang,Zhi-Qiang; Wang,Xin-Yang; Chang,Luke   S.; He,Dalin

doi:10.3892/or.2012.1874

Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway

Authors:
- Liang Liang
- Lei Li
- Jin Zeng
- Yang Gao
- Yu-Le Chen
- Zhi-Qiang Wang
- Xin-Yang Wang
- Luke S. Chang
- Dalin He
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, P.R. China
Published online on: June 19, 2012 https://doi.org/10.3892/or.2012.1874
Pages: 999-1005

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The activation of epidermal growth factor (EGF) through its receptor, EGFR, is one of the major mechanisms that mediate renal cell carcinoma (RCC) metastasis. Silibinin, a natural flavonoid antioxidant with pleiotropic anticancer capability, has shown anti-metastatic effects in a variety of cancers. However, the mechanism by which silibinin inhibits EGFR signal-induced migration and invasion of RCC cells is not clear. Here, we evaluated the potential roles of EGFR signaling cascade that affects RCC progression, and also investigated the inhibitory effect of silibinin on the EGFR signal-induced migration and invasion abilities of RCC cells. Our data indicated that silibinin inhibited migration and invasion of RCC cells in a dose-dependent manner via blocking the EGFR signal, especially in the EGFR highly expressing RCC cells. Silibinin inhibited phosphorylation of EGFR and its downstream molecules ERK1/2 but did not affect phosphorylation of other downstream molecules, STAT3 and Akt, in human RCC cell lines. Moreover, our data suggested that silibinin significantly reduced the MMP-9 expression and its activity that was promoted by the EGFR signal, and also suppressed MMP9-dependent migration and invasion abilities of RCC cells. Taken together, this study clearly demonstrated that silibinin inhibited EGFR induced migration and invasion of RCC cells via blockade of EGFR/MMP-9 signaling. Thus, we suggest that silibinin could be used as a potential effective drug for the inhibition of RCC metastasis.

View Figures

View References

1	Landis SH, Murray T, Bolden S and Wingo PA: Cancer statistics, 1999. CA Cancer J Clin. 49:8–31. 1999.
2	Maldazys JD and DeKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol. 136:376–379. 1986.
3	Li L, Gao Y, Zhang L, Zeng J, He D and Sun Y: Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett. 272:61–69. 2008.
4	Dancey JE: Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol. 22:2975–2977. 2004.
5	Ishikawa J, Maeda S, Umezu K, Sugiyama T and Kamidono S: Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma. Int J Cancer. 45:1018–1021. 1990.
6	Minner S, Rump D, Tennstedt P, et al: Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer. 118:1268–1275. 2012.
7	Hutson TE: Targeted therapies. Oncologist. 16(Suppl 2): 14–22. 2011.
8	Itsumi M and Tatsugami K: Immunotherapy. Clin Dev Immunol. 2010:2845812010.
9	Yang JC, Sherry RM, Steinberg SM, et al: Low reponse rate randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 21:3127–3132. 2003.
10	Velmurugan B, Gangar SC, Kaur M, Tyagi A, Deep G and Agarwal R: Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules. Pharm Res. 27:2085–2097. 2010.
11	Wu KJ, Zeng J, Zhu GD, et al: Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin. 30:1162–1168. 2009.
12	Chen PN, Hsieh YS, Chiang CL, Chiou HL, Yang SF and Chu SC: Silibinin inhibits invasion of oral cancer cells by suppressing the MAPK pathway. J Dent Res. 85:220–225. 2006.
13	Singh RP, Raina K, Sharma G and Agarwal R: Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 14:7773–7780. 2008.
14	Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 10:415–433. 2000.
15	Asakuma J, Sumitomo M, Asano T, Asano T and Hayakawa M: Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma. J Urol. 171:897–902. 2004.
16	Prewett M, Rothman M, Waksal H, Feldman M, Bander NH and Hicklin DJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res. 4:2957–2966. 1998.
17	Rowinsky EK, Schwartz GH, Gollob JA, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 22:3003–3015. 2004.
18	Motzer RJ, Amato R, Todd M, et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs. 21:99–101. 2003.
19	Singh RP and Agarwal R: A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer. Mutat Res. 555:21–32. 2004.
20	Tyagi A, Sharma Y, Agarwal C and Agarwal R: Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells. Pharm Res. 25:2143–2150. 2008.
21	Singh RP, Gu M and Agarwal R: Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 68:2043–2050. 2008.
22	Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC and Lu KH: Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis. 28:977–987. 2007.
23	Chang HR, Chen PN, Yang SF, et al: Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Mol Carcinog. 50:811–823. 2011.
24	Qi L, Singh RP, Lu Y, et al: Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line. Cancer Biol Ther. 2:526–531. 2003.
25	Qiu Q, Yang M, Tsang BK and Gruslin A: EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction. 128:355–363. 2004.
26	Tian YC, Chen YC, Chang CT, et al: Epidermal growth factor and transforming growth factor-beta1 enhance HK-2 cell migration through a synergistic increase of matrix metalloproteinase and sustained activation of ERK signaling pathway. Exp Cell Res. 313:2367–2377. 2007.
27	Kang CS, Pu PY, Li YH, et al: An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J Neurooncol. 74:267–273. 2005.
28	Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A and Hayakawa M: ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res. 10:794–801. 2004.